Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Srnnews

Published November 16, 2026 · Updated November 17, 2026

J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion - SRN News

Read the full story at Srnnews

More Health Headlines. Lilly to buy Calytrix Bio for up to $1.5 billion · Helus Pharma's psychedelic depression drug succeeds in late-stage study,.

Surfaced by this Google Alert

  • Psychedelic biotech